Lawmakers want the new acting head of the Food and Drug Administration to allow sales of Barr Pharmaceuticals Inc's "morning-after" pill without a prescription, according to a letter made public on Tuesday.

Barr has pursued over-the-counter sales of its emergency contraceptive drug, called Plan B, for more than two years

Lawmakers want the new acting head of the Food and Drug Administration to allow sales of Barr Pharmaceuticals Inc's "morning-after" pill without a prescription, according to a letter made public on Tuesday.

Barr has pursued over-the-counter sales of its emergency contraceptive drug, called Plan B, for more than two years

The Perrigo Company announced that through a partnership with InvaGen Pharmaceuticals, it has received final approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets.

Shipment of the product will begin immediately. The product is the generic equivalent to Aventis' Amaryl(R) Tablets, 1 mg, 2 mg and 4 mg, indicated for the treatment of diabetes

The Perrigo Company announced that through a partnership with InvaGen Pharmaceuticals, it has received final approval from the U.S. Food and Drug Administration (FDA) to market Glimepiride Tablets.

Shipment of the product will begin immediately. The product is the generic equivalent to Aventis' Amaryl(R) Tablets, 1 mg, 2 mg and 4 mg, indicated for the treatment of diabetes

Pfizer Inc. announces it has received approval from the U.S. Food and Drug Administration (FDA) to market Aromasin(R) (exemestane tablets) for treatment of postmenopausal women with estrogen-receptor positive early breast cancer.

The treatment is coupled with two-to-three years of tamoxifen, for a total of five consecutive years of hormonal therapy and adjuvant (post- tumor) removal therapy